Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Get a rating) Vice Chairman Padmanabh P. Bhatt sold 700 shares of the company in a trade dated Wednesday, November 9. The stock was sold at an average price of $34.97, for a total transaction of $24,479.00. Following the completion of the sale, the vice president now directly owns 1,644 shares of the company, valued at $57,490.68. The transaction was disclosed in an SEC filing, which is available via the SEC website.
Supernus Pharmaceuticals stock performance
Shares of SUPN Action traded down $0.53 in midday trading on Monday, hitting $34.50. The company’s stock had a trading volume of 535,026 shares, compared to an average volume of 416,544. The stock has a market capitalization of $1.87 billion, a price-earnings ratio of 54.64 and a beta of 0.93. Supernus Pharmaceuticals, Inc. has a 52 week low of $24.95 and a 52 week high of $36.08. The company has a 50-day moving average price of $33.81 and a 200-day moving average price of $31.18.
Changes to analyst ratings
SUPN has been the subject of several analyst reports. Piper Sandler reduced her price target on Supernus Pharmaceuticals from $38.00 to $36.00 in a Tuesday, October 11 research report. StockNews.com cut shares of Supernus Pharmaceuticals from a “strong buy” rating to a “buy” rating in a Tuesday, Oct. 11 research note.
Hedge funds weigh on Supernus Pharmaceuticals
A number of hedge funds have recently bought and sold shares of the company. IndexIQ Advisors LLC bought a new stake in the shares of Supernus Pharmaceuticals in the first quarter for a value of approximately $409,000. TownSquare Capital LLC bought a new stock position in Supernus Pharmaceuticals during Q2 worth $251,000. First Horizon Advisors Inc. bought a new position in Supernus Pharmaceuticals stock in Q2 worth $34,000. Retirement Planning Co of New England Inc. increased its holdings of Supernus Pharmaceuticals shares by 1.3% in the first quarter. Retirement Planning Co of New England Inc. now owns 37,969 shares of the specialty pharmaceutical company worth $1,227,000 after acquiring 488 additional shares during the period. Finally, Stephens Investment Management Group LLC increased its position in Supernus Pharmaceuticals by 1.5% in the first quarter. Stephens Investment Management Group LLC now owns 1,601,344 shares of the specialty pharmaceutical company worth $51,755,000 after buying an additional 23,364 shares in the last quarter. Hedge funds and other institutional investors hold 99.81% of the company’s shares.
Supernus Pharmaceuticals Company Profile
Supernus Pharmaceuticals, Inc, a biopharmaceutical company, is focused on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended-release topiramate indicated for the treatment of epilepsy, as well as for the prophylaxis of migraines; and Oxtellar XR, an extended-release oxcarbazepine for the monotherapy treatment of partial-onset seizures in adults and children aged 6 to 17 years.
Read more
This instant news alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected].
Before you consider Supernus Pharmaceuticals, you’ll want to hear this.
MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market spreads… and Supernus Pharmaceuticals was not on the list.
Although Supernus Pharmaceuticals currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.